As a responsible corporate citizen, we have a commitment to play our part in contributing to UN Global Goal 3 (Ensure healthy lives and promote wellbeing for all at all ages). This Goal includes a target to reduce the number of maternal deaths to under 70 per 100,000 globally.
Ferring has a treatment that can make a difference. Researched and developed as a solution to address unmet needs in women’s health, heat-stable carbetocin remains effective at high temperatures, addressing a significant limitation of oxytocin which must be stored and transported at 2 – 8°C. Once approved, the heat-stable formulation of carbetocin will be made available at an affordable and sustainable access price in public-sector healthcare facilities in low- and lower-middle income countries.This price is a subsidised price of $0.31 +/- 10% per ampoule of 100 µg heat-stable carbetocin. This is comparable to the current United Nations Population Fund price for oxytocin of $0.27 per unit (10 I.U.).
Together with our partners MSD for Mothers and the WHO, we collaborated on the largest clinical study conducted in the prevention of PPH, involving nearly 30,000 women across ten countries.
In June 2018, the results from that study, published in the New England Journal of Medicine demonstrated that our heat-stable formulation of carbetocin is as effective as the current standard of care, oxytocin, for the prevention of PPH. This exciting finding means that Ferring will now be seeking registrations in key countries of need, and start to manufacture heat-stable carbetocin. Our plan is that pending successful submissions in countries such as India, Kenya and Nigeria, we can start to introduce carbetocin into key markets of need in 2020.